{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:53:29Z","timestamp":1791309209364,"version":"4.3.1"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Plexiform neurofibromas arise in up to half of people with neurofibromatosis type 1 (NF1), causing pain, disfigurement and functional loss. Loss of neurofibromin releases RAS\u2013MAPK signaling, making MEK1\/2 a rational target. Two agents are now approved in the United States, the adult indication only since 2025. We evaluated the efficacy and safety of MEK inhibitor monotherapy in NF1-associated symptomatic, inoperable plexiform neurofibroma across children and adults. We searched six databases and registries from inception to 10 July 2026, reporting per PRISMA 2020. The primary outcome was objective response rate (\u226520% tumor volume reduction, REiNS criteria). Two reviewers screened, extracted and appraised studies (RoB 2, ROBINS-I); certainty was rated with GRADE. Proportions were pooled using random-effects models after Freeman\u2013Tukey transformation, with subgrouping by age. Eleven reports of nine studies (528 participants) met eligibility, covering selumetinib, mirdametinib, trametinib and binimetinib. The pooled descriptive response rate was 53.7% (95% CI 40.5\u201366.6; I\n                    <jats:sup>2<\/jats:sup>\n                    \u2009=\u200984.0%) and varied by age: 62.9% in children versus 40.8% in adults. Because eight of the nine strata were single-arm, these are descriptive pooled proportions rather than controlled treatment effects. Adult heterogeneity was driven almost entirely by KOMET, the only randomized trial (20% versus 5% with placebo, p\u2009=\u20090.011); excluding it, the adult estimate was 49.0%. Responses were partial but usually durable, with improvements in pain and quality of life. Toxicity was mostly low grade, with uncommon cardiac and ocular events. MEK inhibition shrinks symptomatic inoperable plexiform neurofibromas in children and adults and is now supported by randomized evidence, although pooled estimates represent a weighted average across four pharmacologically distinct agents rather than a single class effect. Benefit is partial and depends on continued treatment. Optimal duration, comparative effectiveness and any effect on malignant transformation remain undefined.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0359957","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:28:17Z","timestamp":1791307697000},"page":"e0359957","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of MEK inhibitors for NF1-associated symptomatic, inoperable plexiform neurofibromas: A systematic review and meta-analysis"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4738-6356","authenticated-orcid":true,"given":"Sudarshawn","family":"Damodharan","sequence":"first","affiliation":[{"name":"University of Chicago","place":["Chicago, Illinois, United States of America"],"department":["Division of Pediatric Hematology, Oncology and Bone Marrow Transplant"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Tonsgard","sequence":"additional","affiliation":[{"name":"University of Chicago","place":["Chicago, Illinois, United States of America"],"department":["Division of Pediatric Neurology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"pone.0359957.ref001","doi-asserted-by":"crossref","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","article-title":"Neurofibromatosis type 1","volume":"3","author":"DH Gutmann","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"pone.0359957.ref002","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/B978-0-444-52902-2.00053-9","article-title":"Neurofibromatosis type 1 (NF1): Diagnosis and management","volume":"115","author":"RE Ferner","year":"2013","journal-title":"Handb Clin Neurol"},{"issue":"8","key":"pone.0359957.ref003","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41436-021-01170-5","article-title":"Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: An international consensus recommendation","volume":"23","author":"E Legius","year":"2021","journal-title":"Genet Med"},{"issue":"5","key":"pone.0359957.ref004","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrc3911","article-title":"A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor","volume":"15","author":"N Ratner","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"pone.0359957.ref005","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jpeds.2011.08.051","article-title":"Pediatric plexiform neurofibromas: Impact on morbidity and mortality in neurofibromatosis type 1","volume":"160","author":"CE Prada","year":"2012","journal-title":"J Pediatr"},{"key":"pone.0359957.ref006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1750-1172-7-75","article-title":"Growth dynamics of plexiform neurofibromas: A retrospective cohort study of 201 patients with neurofibromatosis 1","volume":"7","author":"R Nguyen","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"pone.0359957.ref007","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/jmg.39.5.311","article-title":"Malignant peripheral nerve sheath tumours in neurofibromatosis 1","volume":"39","author":"DGR Evans","year":"2002","journal-title":"J Med Genet"},{"issue":"17","key":"pone.0359957.ref008","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1200\/JCO.2015.65.3576","article-title":"Distinctive cancer associations in patients with neurofibromatosis type 1","volume":"34","author":"E Uusitalo","year":"2016","journal-title":"J Clin Oncol"},{"key":"pone.0359957.ref009","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3476(97)70092-1","article-title":"Prognostic signs in the surgical management of plexiform neurofibroma: The Children\u2019s Hospital of Philadelphia experience, 1974\u20131994","volume":"131","author":"MN Needle","year":"1997","journal-title":"J Pediatr"},{"issue":"5","key":"pone.0359957.ref010","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/neuonc\/nou004","article-title":"Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"16","author":"BC Widemann","year":"2014","journal-title":"Neuro Oncol"},{"issue":"9","key":"pone.0359957.ref011","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/pbc.25041","article-title":"Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas","volume":"61","author":"BC Widemann","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"pone.0359957.ref012","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/neuonc\/nou235","article-title":"Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: A neurofibromatosis Clinical Trials Consortium phase II study","volume":"17","author":"B Weiss","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"pone.0359957.ref013","first-page":"289","article-title":"Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas","volume":"19","author":"RI Jakacki","year":"2017","journal-title":"Neuro Oncol"},{"issue":"12","key":"pone.0359957.ref014","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/S1470-2045(12)70414-X","article-title":"Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: A phase 2 trial","volume":"13","author":"KA Robertson","year":"2012","journal-title":"Lancet Oncol"},{"issue":"26","key":"pone.0359957.ref015","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1056\/NEJMoa1605943","article-title":"Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas","volume":"375","author":"E Dombi","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"pone.0359957.ref016","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in children with inoperable plexiform neurofibromas","volume":"382","author":"AM Gross","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0359957.ref017","author":"US Food and Drug Administration","year":"2020"},{"key":"pone.0359957.ref018","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1200\/JCO.24.01034","article-title":"ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma","volume":"43","author":"CL Moertel","year":"2025","journal-title":"J Clin Oncol"},{"key":"pone.0359957.ref019","author":"US Food and Drug Administration","year":"2025"},{"key":"pone.0359957.ref020","article-title":"Pharmacokinetics and safety of selumetinib granule formulation in children with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas (SPRINKLE; phase I\/II)","author":"NJ Ullrich","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10496","key":"pone.0359957.ref021","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1016\/S0140-6736(25)00986-9","article-title":"Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): A multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study","volume":"405","author":"AP Chen","year":"2025","journal-title":"Lancet"},{"key":"pone.0359957.ref022","author":"US Food and Drug Administration","year":"2025"},{"key":"pone.0359957.ref023","doi-asserted-by":"crossref","first-page":"10504","DOI":"10.1200\/JCO.2018.36.15_suppl.10504","article-title":"Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)-associated plexiform neurofibroma: a phase I\/IIa study","volume":"36","author":"GB McCowage","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"pone.0359957.ref024","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1093\/neuonc\/noag112","article-title":"TRAM-01: A phase 2 study of trametinib for pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas","volume":"28","author":"D Sadat Kiaei","year":"2026","journal-title":"Neuro Oncol"},{"key":"pone.0359957.ref025","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaa222.619","article-title":"NFB-17. MEK inhibitor binimetinib shows clinical activity in children with neurofibromatosis type 1- associated plexiform neurofibromas: A report from PNOC and the NF Clinical Trials Consortium","volume":"22","author":"S Mueller","year":"2020","journal-title":"Neuro-Oncology"},{"issue":"1","key":"pone.0359957.ref026","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-020-01193-6","article-title":"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial","volume":"27","author":"MJ Fisher","year":"2021","journal-title":"Nat Med"},{"issue":"8","key":"pone.0359957.ref027","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/ph15080956","article-title":"Efficacy and safety of trametinib in neurofibromatosis type 1-associated plexiform neurofibroma and low-grade glioma: A systematic review and meta-analysis","volume":"15","author":"D Wang","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"pone.0359957.ref028","doi-asserted-by":"crossref","first-page":"109478","DOI":"10.1016\/j.clineuro.2026.109478","article-title":"Patient-reported pain outcomes following MEK inhibitor therapy in neurofibromatosis type 1-associated plexiform neurofibromas: A systematic review and meta-analysis","volume":"268","author":"S Sanikommu","year":"2026","journal-title":"Clin Neurol Neurosurg"},{"key":"pone.0359957.ref029","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"MJ Page","year":"2021","journal-title":"BMJ"},{"key":"pone.0359957.ref030","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000435744.57038.af","article-title":"Recommendations for imaging tumor response in neurofibromatosis clinical trials","volume":"81","author":"E Dombi","year":"2013","journal-title":"Neurology"},{"key":"pone.0359957.ref031","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0359957.ref032","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"JA Sterne","year":"2016","journal-title":"BMJ"},{"issue":"9","key":"pone.0359957.ref033","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): Development and validation of a new instrument","volume":"73","author":"K Slim","year":"2003","journal-title":"ANZ J Surg"},{"issue":"7650","key":"pone.0359957.ref034","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"GH Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"3","key":"pone.0359957.ref035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"pone.0359957.ref036","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1214\/aoms\/1177729756","article-title":"Transformations related to the angular and the square root","volume":"21","author":"MF Freeman","year":"1950","journal-title":"Ann Math Stat"},{"issue":"7414","key":"pone.0359957.ref037","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"JPT Higgins","year":"2003","journal-title":"BMJ"},{"issue":"10","key":"pone.0359957.ref038","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1093\/neuonc\/noad086","article-title":"Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1\/2 trial for inoperable plexiform neurofibromas","volume":"25","author":"AM Gross","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"pone.0359957.ref039","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41591-024-03361-4","article-title":"Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: A phase 2 trial","volume":"31","author":"AM Gross","year":"2025","journal-title":"Nat Med"},{"key":"pone.0359957.ref040","doi-asserted-by":"crossref","DOI":"10.1093\/neuonc\/noaf193.043","article-title":"OS04.4.A ReNeu long-term follow-up (LTFU) update: A pivotal, phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic plexiform neurofibroma (PN)","volume":"27","author":"D Babovic-Vuksanovic","year":"2025","journal-title":"Neuro Oncol"},{"issue":"7","key":"pone.0359957.ref041","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1200\/JCO.20.02220","article-title":"NF106: A neurofibromatosis clinical trials consortium Phase II trial of the MEK inhibitor mirdametinib (PD-0325901) in adolescents and adults with NF1-related plexiform neurofibromas","volume":"39","author":"BD Weiss","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"pone.0359957.ref042","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s11060-025-05197-5","article-title":"Real-world experience with selumetinib in children with neurofibromatosis type 1: A multicentric retrospective study","volume":"175","author":"C Santoro","year":"2025","journal-title":"J Neurooncol"},{"issue":"6","key":"pone.0359957.ref043","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/genes16060645","article-title":"Clinical efficacy of selumetinib in alleviating neuropathic pain associated with plexiform neurofibroma: A case series","volume":"16","author":"G Miele","year":"2025","journal-title":"Genes (Basel)"},{"issue":"1","key":"pone.0359957.ref044","article-title":"Selumetinib in pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma: Propensity score analysis of SPRINT vs. natural history control arm","volume":"7","author":"A Adeyemi","year":"2025","journal-title":"Neurooncol Adv"},{"issue":"11","key":"pone.0359957.ref045","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1093\/neuonc\/noac109","article-title":"Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity","volume":"24","author":"AM Gross","year":"2022","journal-title":"Neuro Oncol"},{"key":"pone.0359957.ref046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2017.05.010","article-title":"Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview","volume":"67","author":"MM Miettinen","year":"2017","journal-title":"Hum Pathol"},{"issue":"3","key":"pone.0359957.ref047","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/neuonc\/noae235","article-title":"Consensus recommendations for an integrated diagnostic approach to peripheral nerve sheath tumors arising in the setting of Neurofibromatosis Type 1","volume":"27","author":"C-HG Lucas","year":"2025","journal-title":"Neuro Oncol"},{"issue":"6","key":"pone.0359957.ref048","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/neuonc\/noy013","article-title":"The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors","volume":"20","author":"CS Higham","year":"2018","journal-title":"Neuro Oncol"},{"key":"pone.0359957.ref049","author":"ClinicalTrials.gov"},{"key":"pone.0359957.ref050","author":"ClinicalTrials.gov"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:28:26Z","timestamp":1791307706000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0359957"}},"subtitle":[],"editor":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[{"name":"Tongji University Affilliated East Hospital: Shanghai East Hospital","place":["CHINA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0359957","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}